Ociperlimab With Tislelizumab and Chemotherapy in Participants With Untreated Metastatic Non-Small Cell Lung Cancer

Nonsmall Cell Lung Cancer, Stage IV Clinical Trial

Official title:
AdvanTIG-205: A Phase 2, Randomized Study of Ociperlimab (BGB-A1217) and Tislelizumab With Chemotherapy in Patients With Previously Untreated Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Status Active, not recruiting

Clinical Trial Summary

This is a randomized investigator and participant blinded, sponsor unblinded, multicenter study that evaluates the safety and efficacy of ociperlimab with tislelizumab and histology-based chemotherapy compared with treatment with tislelizumab and histology-based chemotherapy in participants with previously untreated locally advanced, unresectable, or metastatic NSCLC

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Carcinoma, Non-Small-Cell Lung
Lung Neoplasms
Nonsmall Cell Lung Cancer, Stage IV

Clinical Trial Details

NCT number	NCT05014815
Study type	Interventional
Source	BeiGene
Contact
Status	Active, not recruiting
Phase	Phase 2
Start date	November 16, 2021
Completion date	October 2024

View Details

See also
	Status	Clinical Trial	Phase
	Recruiting	`NCT03987087` - A Randomized Study of Primary Tumor Radiotherapy for Patients With MPE Stage IV NSCLC	Phase 2
	Not yet recruiting	`NCT04654520` - A Randomized Study of Primary Tumor Radiotherapy for Patients With Stage Ⅳ NSCLC	N/A